GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Coretech 5 (XPAR:MLCOT) » Definitions » EBIT

Coretech 5 (XPAR:MLCOT) EBIT : €-0.03 Mil (TTM As of Dec. 2022)


View and export this data going back to 2016. Start your Free Trial

What is Coretech 5 EBIT?

Coretech 5's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2022 was €-0.03 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2022 was €-0.03 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Coretech 5's annualized ROC % for the quarter that ended in Dec. 2022 was -52.38%. Coretech 5's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Coretech 5's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -9.19%.

Coretech 5 EBIT Historical Data

The historical data trend for Coretech 5's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coretech 5 EBIT Chart

Coretech 5 Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only -0.13 -0.21 -0.11 -0.14 -0.03

Coretech 5 Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT Get a 7-Day Free Trial Premium Member Only -0.13 -0.21 -0.11 -0.14 -0.03

Competitive Comparison of Coretech 5's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Coretech 5's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coretech 5's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Coretech 5's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Coretech 5's EV-to-EBIT falls into.


Coretech 5 EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was €-0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coretech 5  (XPAR:MLCOT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Coretech 5's annualized ROC % for the quarter that ended in Dec. 2022 is calculated as:

ROC % (Q: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2021 ) + Invested Capital (Q: Dec. 2022 ))/ count )
=-0.033 * ( 1 - 0% )/( (0.035 + 0.091)/ 2 )
=-0.033/0.063
=-52.38 %

where

Invested Capital(Q: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.067 - 0.177 - ( 0 - max(0, 0.177 - 0.032+0))
=0.035

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.105 - 0.072 - ( 0 - max(0, 0.072 - 0.014+0))
=0.091

Note: The Operating Income data used here is one times the annual (Dec. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Coretech 5's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2022 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2021  Q: Dec. 2022
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.033/( ( (0 + max(-0.145, 0)) + (0 + max(-0.058, 0)) )/ 2 )
=-0.033/( ( 0 + 0 )/ 2 )
=-0.033/0
= %

where Working Capital is:

Working Capital(Q: Dec. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.032) - (0.177 + 0 + 0)
=-0.145

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.014) - (0.072 + 0 + 0)
=-0.058

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Coretech 5's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2022 )
=-0.033/0.359
=-9.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coretech 5 EBIT Related Terms

Thank you for viewing the detailed overview of Coretech 5's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Coretech 5 (XPAR:MLCOT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Coretech 5 (XPAR:MLCOT) » Definitions » EBIT
Comparable Companies
XPAR:ALRPD ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085 XPAR:IPN SHSE:600196 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
5 rue de Castiglione, Paris, FRA, 75 001
Website
https://www.coretech5.com
Coretech 5 Formerly Gour Medical AG is a pharmaceutical company. It develops and markets veterinary medicines and specialist pet. Its products include food supplements or nutraceuticals or related medical devices. The products are dedicated to the treatment of pain, allergies, behavioral disorders and improvement of quality of life. It sells its product under the brand Weedley.

Coretech 5 (XPAR:MLCOT) Headlines

No Headlines